← Back to headlines
Ocugen Doses First Patient in Phase 3 Gene Therapy Trial for Macular Degeneration
Ocugen has initiated its pivotal Phase 3 registrational trial for OCU410, an experimental modifier gene therapy targeting geographic atrophy secondary to dry age-related macular degeneration.
1 Sept, 11:02 — 1 Sept, 11:02
Related Stories
Irish Health Agency Fined €645,000 for Storing Records in Derelict Sites
2h ago
New Urine Test Detects Over 90 Percent of Bladder Cancer Cases
2h ago
Swimmer Hospitalized Following Suspected Shark Attack in Massachusetts
6h ago
Wellington Clinics Suspends Kidney Transplants Amid Organ Harvesting Probe
11h ago